Interestingly, one study in waldenstrom macroglobulinemia patients with newly diagnosed COVID-19 found that oral ibrutinib at a regular 420 mg d−1 dosing improved oxygenation and decreased inflammatory cytokines of patients, implicating a pro-inflammatory role of BTK in COVID-19 [138]. Here, BTK is linked to COVID-19.